CNS Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ under the ticker CNSP. For French, Belgian, and Swiss investors, it should be viewed as a micro- to small-cap biotechnology name with a high clinical-development risk profile and a strategy centered on cancers of the brain and central nervous system. The company has historically focused on glioblastoma multiforme (GBM), one of the most aggressive and lethal brain cancers, and in March 2026 it announced a broader corporate strategy aimed at building a higher-value neurology and oncology pipeline, including the search for external assets and out-licensing opportunities. That shift is important because it indicates management’s intention to reduce dependence on a single lead program and to reposition the company toward a more diversified pipeline. The company’s core legacy asset is Berubicin, a synthetic second-generation anthracycline designed to cross the blood-brain barrier. CNS Pharmaceuticals has evaluated Berubicin in multiple clinical studies, including a late-stage global trial in recurrent or progressive GBM. In March 2025, the company reported primary analysis results showing clinically relevant outcomes and a favorable safety profile, but it did not achieve a statistically significant improvement in overall survival, the primary endpoint. This is a typical binary-risk situation for development-stage biotech investors: the science can generate meaningful clinical signals, but valuation remains highly sensitive to trial outcomes, regulatory milestones, and financing needs. In parallel, CNS continues to advance TPI 287, a novel taxane for CNS oncology, with published clinical data in GBM. From a competitive standpoint, CNS operates in a highly crowded space dominated by large pharmaceutical companies and a long list of oncology-focused biotechs. Its investment case is therefore not based on current commercial scale, but on the potential to create value through differentiated science, targeted clinical development, and regulatory advantages. The company highlights orphan-drug designation for Berubicin, along with prior Fast Track status, both of which can support development efficiency and future exclusivity if approval is achieved. Geographically, CNS is headquartered in Houston, Texas, and its operating footprint is primarily U.S.-centric, although clinical development and partnering activity may extend internationally. In short, CNS Pharmaceuticals is a U.S. clinical-stage biotech listed on the NASDAQ whose equity story depends on CNS oncology pipeline execution, pipeline expansion, and the ability to convert scientific assets into regulatory and commercial value.